The search for AMPA/Gly(N) receptor antagonists

Drugs of the Future

Volumn 24, Issue 10, 1999, Pages 1107-1124

  Nikam, Sham S ^a   Bigge, Christopher F ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [5 (4 DIMETHYLSULFAMOYLPHENYL) 6,7,8,9 TETRAHYDRO 8 METHYL 2 OXO 1H PYRROLO[3,2 H]ISOQUINOLIN 3 YLIMINOXY] 4 HYDROXYBUTYRIC ACID; 3 (2 CARBOXY 2 PHENYLETHENYL) 4,6 DICHLORO 1H INDOLE 2 CARBOXYLIC ACID; 4 METHYLGLUTAMIC ACID; 5 [4 AMINOMETHYL 2 (CARBOXYMETHOXY)PHENYLCARBAMOYLMETHYL] 9 CHLORO 6,7 DIHYDRO 1H,5H PYRIDO[1,2,3 DE]QUINOXALINE 2,3 DIONE; 5,7 DICHLORO 1,2,3,4 TETRAHYDRO 4 (3 PHENYLUREIDO) 2 QUINOLINECARBOXYLIC ACID; 6 (1 IMIDAZOLYL) 7 NITRO 2,3 QUINOXALINEDIONE; 6,7 DICHLORO 5 NITRO 2,3 QUINOXALINEDIONE; 7 CHLORO 4 HYDROXY 3 (3 PHENOXYPHENYL) 2 QUINOLONE; ACEA 1416; AMPA RECEPTOR; AMPA RECEPTOR ANTAGONIST; DECAHYDRO 6 [2 (1H TETRAZOL 5 YL)ETHYL] 3 ISOQUINOLINECARBOXYLIC ACID; EXCITATORY AMINO ACID RECEPTOR; L 698544; LY 292025; LY 301199; LY 377770; MRZ 2570; MRZ 2571; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NS 257; PROBENECID; RPR 104632; UNCLASSIFIED DRUG; [[3,4 DIHYDRO 7 MORPHOLINO 2,3 DIOXO 6 (TRIFLUOROMETHYL) 1(2H) QUINOXALINYL]METHYL]PHOSPHONIC ACID;

CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; DRUG EFFICACY; DRUG POTENCY; HUMAN; NEUROPROTECTION; REVIEW;

EID: 0032720692     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1999.024.10.858631     Document Type: Review

References (122)

1. Hollmann, M., O'Shea-Greenfield, A., Rogers, S.W., Heinemann, S. Cloning by functional expression of a member of the glutamate receptor family. Nature 1989, 342: 643-8.
2. Keinanen, K., Wisden, W., Sommer, B. et al. A family of AMPA-selective glutamate receptors. Science 1990, 249: 556-60.
3. Muir, K.W., Lees, K.R. Clinical experience with excitatory amino acid antagonist drugs. Stroke 1995, 26: 503-13.
4. Hollmann, M., Heinemann, S. Cloned glutamate receptors. Ann Rev Neurosci 1994, 17: 31-108.
5. Kuusinen, A., Aruola, M., Keinaen, K. Molecular dissection of the agonist binding site of an AMPA receptor. EMBO J 1995, 14: 6327-32.
6. Lees, G.J. Therapeutic potential of AMPA receptor. Ligands in neurological disorders. CNS Drugs 1996, 5: 51-74.
7. Doble, A. Excitatory amino acid receptors and neurodegeneration. Therapie 1995, 50: 319-37.
8. Fletcher, E.J., Lodge, D. New developments in the molecular pharmacology of α-amino-3-hydroxy-5-methyl-4-isoxazole-propionate and kainate receptors. Pharmacol Ther 1996, 70: 65-89.
9. Bettler, B., Mulle, C. Neurotransmitter receptors II, AMPA and kainate receptors. Neuropharmacology 1995, 34: 123-9.
10. Paas, Y. The macro and micro architectures of the ligand-binding domain of glutamate receptors. Trends Neurosci 1998, 21: 117-25.
11. Sutcliffe, M.J., Wo, Z.G., Oswald, R.E. Three dimensional models of non-NMDA glutamate receptors. Biophys J 1996, 70: 1575-89.
12. Gaspary, H.L. AMPA receptors: Players in calcium-mediated neuronal injury. Neuroscientist 1998, 4: 149-53.
13. Johnson, J.W., Asher, P. Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature 1987, 325: 529-31.
14. Olney, J.W., Farber, N.B. NMDA antagonists as neurotherapeutic drugs, psychotogens, neurotoxins and research tools for studying schizophrenia. Neuropsychopharmacology 1995, 13: 335-45.
15. Nakanishi, S. Molecular diversity of glutamate receptors and implications for brain function. Science 1992, 258: 597-630.
16. Mori, H., Mishina, M. Structure and function of the NMDA receptor channel. Neuropharmacology 1995, 34: 1219-37.
17. Hira, H., Kirsch, J., Laube, B., Betz, H., Kuhse, J. The glycine binding site of the N-methyl-D-aspartate receptor subunit NR1: Identification of novel determinants of co-agonist potentiation in the extracellular M3-M4 loop region. Proc Natl Acad Sci USA 1996, 93: 6031-6.
18. 3H]-(2S,4R)-4-methylglutamate: Pharmacological characterization in rabbit brain membranes. Neuropharmacology 1997, 36: 1483-8.
19. Huettner, J.E. Functional properties of kainate receptors. In: The lonotropic Glutamate Receptors. Monaghan, D.T., Wenthold, R.J. (Eds.). Humana Press: Totowa 1997, 265-83.
20. Henley, J.M. Kainate-binding proteins: Phytogeny, structures and possible functions. TIPS Rev 1994, 15: 182-90.
21. Loscher, W., Wluz, P., Rundfeldt, C., Baran, H., Hoenack, D. Anticonvulsant effects of the glycine/NMDA receptor ligands D-cycloserine and D-serine but not R-(+)-HA-966 in amygdalakindled rats. Br J Pharmacol 1994, 112: 97-106.
22. Mori, J.L., Price, M.T., Bai, H.Y. et al. Blockade of both NMDA and non-NMDA receptors in required for optimal protection against ischemic neuronal degeneration in the in vivo adult mammalian retina. Exp Neural 1991, 113: 10-7.
23. Borowicz, K.K., Gasior, M., Kleinbrok, Z., Czuczwar, S.J. The non-competitive AMPA/KA receptor antagonist, GYKI52466, potentiates the anticonvulsant activity of conventional antiepileptics. Eur J Pharmacol 1995, 281: 319-26.
24. Rosenmund, C. Stern-Back, Y., Stephens, C.F. Glutamate receptor activation: A four-step program. Science 1998, 280: 1596-9.
25. Sutcliffe, M.J., Wo, Z.G., Oswald, R.E. Three-dimensional models of non-NMDA glutamate receptors. Biophys J 1996, 70: 1575-89.
26. Ebert, B., Madsen, U., Soby, K.K., Krogsgaard-Larsen, P. Functional partial agonism at ionotropic excitatory amino acid receptors. Neurochem Int 1996, 29: 309-16.
27. Moltzen, S.L., Falch, E., Bogeso, K.P., Krogsgaard-Larsen, P. 5-Arylisoxazolyl-4-substituted 2-amino carboxylic acid compounds. PCT Int Appl 9512587.
28. Johansen, T.N., Ebert, B., Falch, E., Krogsgaard-Larsen, P. AMPA receptor agonists: Resolution, configurational assignment, and pharmacology of (+)-(S)-and (-)-(R)-2-amino-3-[3-hydroxy-5-(2-pyridyl)-isoxazol-4-yl]-propionic acid (2-Py-AMPA). Chirality 1997, 9: 274-80.
29. Falch, E., Brehm, L., Mikkelsen, I. et al. Heteroarylanalogues of AMPA. 2. Synthesis, absolute stereochemistry, photochemistry and structure-activity relationships. J Med Chem 1998, 41: 2513-23.
30. Bang-Anderson, B., Lenz, S.M., Skjaerbaek, N. et al. Heteroaryl analogues of AMPA. Synthesis and quantitative structure-activity relationships. J Med Chem 1997, 40: 2831-42.
31. Conti, P., De Amici, M., De Sarro, G. et al. Synthesis and pharmacology of a new AMPA-kainate receptor agonist with potent convulsant activity. J Med Chem 1998, 41: 3759-62.
32. Zhou, L-M., Gu, Z-Q., Costa, A.M. et al. Methylglutamic acid (SYM 2081): A selective, high affinity ligand for kainate receptors. J Pharmacol Exp Ther 1997, 280: 422-7.
33. Omstein, P.L., Arnold, M.B., Augenstein, N.K., Lodge, D., Leander, J.D., Schoepp, D.D.J. 3SR,4aRS,6RS,8aRS-6-(2-(1H-tetrazol-5-yl)ethyl)-decahydroisoquinoline-3- carboxylic acid: A structurally novel, systemically active, competitive AMPA receptor antagonist. J Med Chem 1993, 36: 2046-8.
34. Ornstein, P.L., Arnold, M.B., Allen, N.K. et al. Structure-activity studies of 6-(tetrazolylalkyl)-substituted decahydroisoquinoline-3-carboxylic acid AMPA receptor antagonists. 1. Effects of stereochemistry, chain length, and chain substitution. J Med Chem 1996, 39: 2219-31.
35. Schoepp, D.D., Lodge, D., Bleakman, D. et al. In vitro and in vivo antagonism of AMPA receptor activation by (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydmisoquinoline-3- carboxylic acid. Neuropharmacology 1995, 34: 1159-68.
36. Bleakman, D., Schoepp, D.D., Ballyk, B. et al. Pharmacological discrimination of GluR5 and GluR6 kainate receptor subtypes by (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3- carboxylic acid. Mol Pharmacol 1996, 49: 581-5.
37. Bleisch, T.J., Ornstein, P.L., Alien, N.K., Wright, R.A., Lodge, D., Schoepp, D.D. Structure-activity studies of aryl-spaced decahydroisoquinoline-3-carboxylic acid AMPA receptor antagonists. Bioorg Med Chem Lett 1997, 7: 1161-6.
38. O'Neill, M.J., Bond, A., Ornstein, P.L. et al. Decahydroisoquinolines: Novel competitive AMPA/kainate antagonists with neuroprotective effects in global cerebral ischemia. Neuropharmacology 1998, 37: 1211-22.
39. Arnold, M.B., Ornstein, P.L, Alien, N.K. et al. Synthesis and evaluation of diphenyl ether and decalin amino acids as AMPA antagonists. 212th ACS Natl Meet (Aug 25-29, Orlando) 1996, MEDI-074.
40. Bigge, C.F., Boxer, P.A., Ortwine, D.F. AMPA/kainate receptors. Curr Pharm Des 1996, 2: 397-412.
41. Bigge, C.F., Nikam, S.S. AMPA receptor agonists, antagonists and modulators: Their potential for clinical utility. Exp Opin Ther Patents 1997, 7: 1099-114.
42. Johnson, G., Ornstein, P.L. Competitive NMDA antagonists -A comprehensive analysis of molecular biological, structure activity and molecular modeling relationships. Curr Pharm Des 1996, 2: 331-56.
43. Dannhardt, G., Kohl, B.K. The glycine site on the NMDA receptor: Structure-activity relationships and possible therapeutic applications. Curr Med Chem 1998, 5: 253-63.
44. Sheardown, M.J., Nielson, E.O., Hansen, A.J., Jacobsen, P., Honore, T. 2,3-Dihydroxy-6-nitro-7-sulfamoylbenzo(F)quinoxaline: A neuroprotectant for cerebral ischemia. Science 1990, 247: 571-4.
45. Bigge, C.F., Malone, T.C., Boxer, P.A. et al. Synthesis of 1,4,7,8,9,10-hexahydro-9-methyl-6-nitropyrido[3,4-f]-quinoxaline-2,3-dione and related quinoxalinediones: Characterization of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (and N-methyl-D-aspartate) receptor and anticonvulsant activity. J Med Chem 1995, 38: 3720-40.
46. Birch, P.J., Grossman, C.J., Hayes, A.G. 6,7-Dinitro-quinoxaline-2,3-dione and 6-nitro-7-cyano-quinoxaline-2,3-dione antagonize responses to NMDA in the rat spinal chord via an action at the strychnine-insensitive glycine receptor. Eur J Pharmacol 1988, 156: 177-80.
47. Neuman, R.S., Ben-Ari, Y., Gho, M., Cherubini, E. Blockade of excitatory synaptic transmission by 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) in the hippocampus in vitro. Neurosci Lett 1988, 92: 64-8.
48. Ohmori, J., Sakamoto, S., Kubota, H. et al. 6-(1H-Imidazol-1-yl)-7-nitro-2,3(1H,4H)-quinoxalinedione hydrochloride (YM90K) and related compounds: Structure-activity relationships for the AMPA-type non-NMDA receptor. J Med Chem 1994, 37: 467-75.
49. Watjen, F., Bigge, C.F., Jensen, L.H. et al. NS 257 (1,2,3,6,7,8-hexahydro-3(hydroximino)-N,N,7-trimethyl-2-oxobenzo[2,1-b:3,4-c'] dipyrrole-5-sulfonamide) is a potent, systemically active AMPA receptor antagonist. Bioorg Med Chem Lett 1994, 4: 371-6.
50. Watjen, F., Drejer, J. Preparation of novel indole-2,3-dione-3-oximes as glutamate receptor antagonists. WO 9814447.
51. Leeson, P.D., Carling, R.W., Moore, K.W. et al. 4-Amido-2-carboxytetrahydroquinolines. Structure-activity relationships for antagonism at the glycine site of the NMDA receptor. J Med Chem 1992,35: 1954-68.
52. Cai, S.X., Zhou, Z-L., Huang, J-C. et al. Structure-activity relationships of 4-hydroxy-3-nitroquinolin-2(1H)-ones as novel antagonists at the glycine site of N-methyl-D-aspartate receptors. J Med Chem 1996, 39: 4682-6.
53. 17O NMR studies of electronic and steric interactions of substituted quinoxaline-2(1H),3(4H)-diones. J Heterocycl Chem 1996, 33: 643-6.
54. 14N NMR studies of quinoxaline-2(1H),3(4H)-diones and N,N'-substituted oxamides: The first experimental evidence of torsion angle deformation resulting from an unprecedented through six-bond substituent effect on the diamide group of quinoxaline-2(1H),3(4H)-diones. Tetrahedron Lett 1996, 37: 3191-4.
55. Hoelscher, P., Turski, L. Preparation of benzo[f]quinoxalinediones as quisqualate receptor ligands. DE 4314592.
56. Lubisch, W., Vierling, M., Behl, B., Hofmann, H-P. Preparation of (pyrrolyl)-5,6,7,8-tetrabenzo[f]quinoxaline-2,3-dione neurotransmitter antagonists. DE 4436852.
57. Sager, T.N., Moller, A., Watjen, F., Paulson, O.B., Drejer, J. NS 1209 (SPD502), a new selective AMPA antagonist, reduces the infarct size in rats following permanent occlusion of the middle cerebral artery. Personal communication, 1998.
58. Nagata, R., Tanno, N., Kodo, T. et al. Tricyclic quinoxalinediones: 5,6-dihydro-1H-pyrrolo[1,2,3-de]quinoxaline-2,3-diones and 6,7-dihydro-1H,5H-pyrido[1,2,3-de]quinoxaline-2,3-diones as potent antagonists for the glycine binding site of the NMDA receptor. J Med Chem 1994, 37: 3956-68.
59. Krueger, M., Seelen, W., Turski, L. Preparation of pyrido[1,2,3-de]quinoxalines as antagonists of excitatory amino acids with high affinity for AMPA receptors. DE 4314593.
60. Ciba-Geigy AG. EP 705835, AU 9530287, AU 9527116.
61. Cai, S.X., Keana, J.F.W., Martin, V.V. Preparation of 4,5-bridged quinoxalinediones and quinolones as excitatory amino acid receptor antagonists. WO 9640141.
62. Jacobsen, P., Nielsen, F.E. Triazoloquinoxalin-1,4-diones and their preparation and use. US 5504085.
63. Jacobsen, P., Nielsen, F.E., Jeppesen, L. Heterocyclic compounds, their use and preparation. US 5559106.
64. Jeppesen, L. Imidazo[1,2-a]quinoxalinone derivatives and their preparation and use as AMPA receptor antagonists. WO 9521842.
65. Ohmori, J., Shimizu-Sasamata, M., Okada, M., Sakamoto, S. 8-(1H-Imidazol-1-yl)-7-nitro-4(5H)-imidazo[1,2-a]quinoxalinone and related compounds: Synthesis and structure-activity relationships for the AMPA-type non-NMDA receptor. J Med Chem 1997, 40: 2053-63.
66. Treiber, H., Lubisch, W., Behl, B., Hofmann, H.P. Imidazoloquinoxalinones for the treatment of CNS disorders. US 5538972.
67. Aloup, J., Bouquerel, J., Damour, D. et al. 5H,10H-Imidazo[1,2-a]indeno[1,2-e]pyrazin-4-one derivatives, useful as AMPA and NMDA receptor antagonists, their preparation and intermediates, and drugs containing them. WO 9725328.
68. Aloup, J., Damour, D., Hardy, J. et al. Preparation of indeno[1,2-e]pyrazin-4-ones as quisqualate and NMDA receptor antagonists. WO 9710246.
69. Aloup, J., Audiau, F., Barreau, M. et al. Preparation of 5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazin-4-ones as AMPA and NMDA receptor antagonists. WO 9631511.
70. Subramanyam, C., Ault, B., Sawutz, D. et al. 6-(4-Pyridinyl)-1H-1,2,3-triazolo[4,5-d]-pyrimidin-4(5H)-one: A structurally novel competitive AMPA receptor antagonist. J Med Chem 1995, 38: 587-9.
71. Sakamoto, S., Ohmori, J., Shishikura, J., Shimizu-Sasamata, M., Okada, M. Novel AMPA/kainate receptor antagonists. Medicinal Chemisty: Today Tomorrow. Proc AFMC Int Med Chem Symp 1997, 271-8.
72. Shimizu-Sasamata, M., Kawasaki-Yatsugi, S., Okada, M. et al. YM90K: Pharmacological characterization as a selective and potent α-amino-4-hydroxy-5-methylisoxazole-4-propionate/ kainate receptor antagonist. J Pharmacol Exp Ther 1996, 276: 84-92.
73. Kawasaki-Yatsugi, S., Ichiki, C., Yatsugi, S., Shimizu-Sasamata, M., Yamaguchi, T. YM90K, an AMPA receptor antagonist, protects against ischemic damage caused by permanent and transient middle cerebral artery occlusion in rats. Naunyn-Schmied Arch Pharmacol 1998, 358: 586-91.
74. Kawasaki-Yatsugi, S., Shimizu-Sasamata, M., Yatsugi, S., Yamaguchi, T. Delayed treatment with YM90K, an AMPA receptor antagonist, protects against ischemic damage after middle cerebral artery occlusion in rats. J Pharm Pharmacol 1998, 50: 891-8.
75. Ohmori, J., Shimizu-Sasamata, M., Okada, M., Sakamoto, S. Novel AMPA receptor antagonists: Synthesis and structure-activity relationships of 1-hydroxy-7-(1H-imidazol-1-yl)-6-nitro-2,3(1H,4H)-quinoxalinedione and related compounds. J Med Chem 1996, 39: 3971-9.
76. Ohmori, J., Kubota, H., Shimizu-Sasamata, M., Okada, M., Sakamoto, S. Novel α-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonists: Synthesis and structure-activity relationships of 6-(1H-imidazol-1-yl)-7-nitro-2,3(1H,4H)-pyrido[2,3-b]pyrazinedione and related compounds. J Med Chem 1996, 39: 1331-8.
77. Takahashi, M., Ni, J.W., Kawasaki-Yatsugi, S. et al. Neuroprotective efficacy of YM872, an α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist, after permanent middle cerebral artery occlusion in rats. J Pharmacol Exp Ther 1998, 287: 559-66.
78. Shimizu-Sasamata, M., Kano, T., Rogowska, J., Wolf, G.L., Moskowitz, M.A., Lo, E.H. YM872, a highly water-soluble AMPA receptor antagonist, preserves the hemodynamic penumbra and reduces brain injury after permanent focal ischemia in rats. Stroke 1998, 29: 2141-7.
79. Kohara, A., Okada, M., Tsutsumi, R. et al. In-vitro characterization of YM872, a selective, potent and highly water-soluble α-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist. J Pharm Pharmacol 1998, 50: 795-801.
80. Kawasaki-Yatsugi, S., Yatsugi, S., Takahashi, M. et al. A novel AMPA receptor antagonist, YM872, reduces infarct size after middle cerebral artery occlusion in rats. Brain Res 1998, 793: 39-46.
81. Lubisch, W., Behl, B., Hofmann, H.P. Pyrrolylquinoxalinediones: A new class of AMPA receptor antagonists. Bioorg Med Chem Lett 1996, 6: 2887-92.
82. Lubisch, W., Behl, B., Hofmann, H.P. Pyrrolylquinoxalinediones: The importance of pyrrolic substitution on AMPA receptor binding. Bioorg Med Chem Lett 1997, 7: 1101-6.
83. Lubisch, W., Behl, B., Hofmann, H.P., Teschendorf, H.J. Pyrrolylquinoxalinediones: Dicarboxylates as highly potent AMPA receptor antagonists. Bioorg Med Chem Lett 1997, 7: 2441-6.
84. Takada, S., Sasaya, T., Chomei, N., Eigyo, M., Kawasaki, K. Preparation of arylthioquinoxaline derivatives as antagonists of glutamate receptors. JP 08059660.
85. Takada, S., Chomei, N., Adachi, M., Eigyo, M., Kawasaki, K. Preparation of oxopyridinylquinoxaline derivatives as antagonists of N-methyl-D-aspartate (NMDA) and 2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propanoate (AMPA) receptors. EP 676397.
86. Auberson, Y.P., Bischoff, S., Moretti, R., Schmutz, M., Veenstra, S.J. 5-Aminomethylquinoxaline-2,3-diones, Part I: A novel class of AMPA receptor antagonists. Bioorg Med Chem Lett 1998, 8: 65-70.
87. Auberson, Y.P., Acklin, P., Allgeier, H. et al. 5-Aminomethylquinoxaline-2,3-diones. Part II: N-Aryl derivatives as novel NMDA/glycine and AMPA antagonists. Bioorg Med Chem Lett 1998, 8: 71-4.
88. Acklin, P., Allgeier, H., Auberson, Y.P. et al. 5-Aminomethylquinoxaline-2,3-diones. Part III: Arylamide derivatives as highly potent and selective glycine-site NMDA receptor antagonists. Bioorg Med Chem Lett 1998, 8: 493-8.
89. Auberson, Y.P., Acklin, P., Bischoff, S. et al. N-Phosphonoalkyl-5-aminomethylquinoxaline-2,3-diones: In vivo active AMPA and NMDA(glycine) antagonists. Bioorg Med Chem Lett 1999, 9: 249-54.
90. Mowbray, C.E., Stobie, A., Bull, D.J., Carr, C.L., Fray, M. J. Preparation of quinoxalinediones as NMDA receptor antagonists. WO 9608485.
91. N receptor antagonists: Amino acid derivatives. J Med Chem 1999, 42: 2266-71.
92. Nikam, S.S. Amino acid derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists. US 5614508.
93. Nikam, S.S., Rafferty, M.F., Komberg, B.E. Alkylamine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists. US 5654303.
94. Nikam, S.S., Rafferty, M.F., Kornberg, B.E., Yuen, P.W. Cyclic amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists. US 5874426.
95. Nikam, S.S. Amide derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists. WO 9746539.
96. N receptor antagonists. 215th ACS Natl Meet (Mar 29-Apr 2, Dallas) 1998, MEDI-014.
97. Turski, L., Huth, A., Sheardown, M. et al. ZK200775. A phosphonate quinoxalinedione AMPA antagonist for neuroprotection in stroke and trauma. Proc Natl Acad Sci USA 1998, 95: 10960-5.
98. Epperson, J.R., Hewawasam, P., Meanwell, N.A., Boissard, C. G., Gribkoff, V.K., Post-Munson, D. Synthesis and excitatory amino acid pharmacology of some novel quinoxalinediones. Bioorg Med Chem Lett 1993, 3: 2801-4.
99. Rowley, M., Kulagowski, J., Watt, A.P. et al. Effect of plasma protein binding on in vivo activity and brain penetration of glycine/NMDA receptor antagonists. J Med Chem 1997, 40: 4053-68.
100. Keana, J.F.W., Kher, S., Cai, S.X. et al. Synthesis and structure-activity relationships of substituted 1,4-dihydroquinoxaline-2,3-diones: Antagonists of N-methyl-D-aspartate (NMDA) receptor glycine sites and non-NMDA glutamate receptors. J Med Chem 1995, 38: 4367-79.
101. Lingenhohl, K., Pozza, M.F. Reevaluation of ACEA-1021 as an antagonist at the strychnine-insensitive glycine site of N-methyl-D-aspartate receptors. Neuropharmacology 1998, 37: 729-37.
102. Warner, D.S., Martin, H., Ludwig, P., McAllister, A., Keana, J.F.W., Weber, E. In vivo models of cerebral ischemia: Effects of parenterally administered NMDA receptor glycine site antagonists. J Cereb Blood Flow Metab 1995, 15: 188-96.
103. Takaoka, S., Bart, R.D., Pearlstein, R., Brinkhous, A., Warner, D.S. Neuroprotective effect of NMDA receptor glycine recognition site antagonism persists when brain temperature is controlled. J Cereb Blood Flow Metab 1997, 17: 161-7.
104. Morimoto, Y., Wu, B., Bart, R.D., Morimoto, Y., Pearlstein, R.D., Warner, D.S. Effects of NMDA receptor glycine recognition site antagonism on cerebral metabolic rate for glucose and cerebral blood flow in the conscious rat. Brain Res 1998, 779: 170-6.
105. Balster, R.L., Mansbach, R.S., Shelton, K.L et al. Behavioral pharmacology of two novel substituted quinoxalinedione glutamate antagonists. Behav Pharmacol 1995, 6: 577-89.
106. Hawkinson, J.E., Huber, K.R., Sahota, P.S., Hsu, H.H., Weber, E., Whitehouse, M.J. The N-methyl-D-aspartate (NMDA) receptor glycine site antagonist ACEA-1021 does not produce pathological changes in rat brain. Brain Res 1997, 744: 227-34.
107. Auer, R.N. Structural neurotoxicologic investigation of the glycine antagonist 5-nitro-6,7-dichloroquinoxalinedione (ACEA-1021). NeuroToxicology 1997, 18: 53-62.
108. Cai, S.X., Kher, S.M., Zhou, Z-L. et al. Structure-activity relationships of alkyl-and alkoxy-substituted 1,4-dihyroquinoxaline-2,3-diones: Potent and systemically active antagonists for the glycine site of the NMDA receptor. J Med Chem 1997, 40: 730-8.
109. Ilyin, V.I., Whittemore, E.R., Tran, M. et al. Pharmacology of ACEA-1416: A potent systemically active NMDA receptor glycine site antagonist. Eur J Pharmacol 1996, 310: 107-14.
110. Cai, S.X., Zhou, Z-L., Huang. J-C. et al. Synthesis and structure-activity relationships of 1,2,3,4-tetrahydroquinolin-2,3,4-trione 3-oximes: Novel and highly potent antagonists for NMDA receptor glycine site. J Med Chem 1996, 39: 3248-55.
111. Guzikowski, A.P., Cai, S.X., Espitia, S. et al. Analogs of 3-hydroxy-1H-1-benzazepine-2,5-dione: Structure-activity relationship at N-methyl-D-aspartate receptor glycine sites. J Med Chem 1996, 39: 4643-53.
112. Danysz, W., Parsons, C.G., Karcz-Kubicha, M. et al. Glycine B antagonists as potential therapeutic agents. Previous hopes and present reality. Amino Acids 1998, 14: 235-9.
113. Nagata, R., Ae, N., Tanno, N. Structure-activity relationships of tricyclic quinoxalinediones as potent antagonists for the glycine site of the NMDA receptor 1. Bioorg Med Chem Lett 1995, 5: 1527-32.
114. Carling, R.W., Leeson, P.D., Moore, K.W. et al. 3-Nitro-3,4-dihydro-2(1H)-quinolones. Excitatory amino acid antagonists acting at glycine-site NMDA and (RS)-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors. J Med Chem 1993, 36: 3397-408.
115. Jimonet, P., Audiau, F., Aloup, J-C. et al. Synthesis and SAR of 2H-1,2,4-benzothiadiazine-1,1-dioxide-3-carboxylic acid derivatives as novel potent glycine antagonists of the NMDA receptor-channel complex. Bioorg Med Chem Lett 1994, 4: 2735-40.
116. Boireau, A., Malgouris, C., Burgevin, M-C. et al. Neuroprotective effects of RPR 104632, a novel antagonist at the glycine site of the NMDA receptor, in vitro. Eur J Pharmacol 1996, 300: 237-46.
117. Balsamini, C., Bedini, A., Diamantini, G., Spadoni, G., Tontini, A., Tarzia, G. (E)-3-(2-(N-Phenylcarbamoyl)vinyl)pyrrole-2-carboxylic acid derivatives. A novel class of glycine site antagonists. J Med Chem 1998, 41: 808-20.
118. Di Fabio, R., Capelli, A.M., Conti, N. et al. Substituted indole-2-carboxylates as in vivo potent antagonists acting as the strychnine-insensitive glycine binding site. J Med Chem 1997, 40: 841-50.
119. Baron, B.M., Harrison, B.L., Kehne, J.H. et al. Pharmacological characterization of MDL 105,519, an NMDA receptor glycine site antagonist. Eur J Pharmacol 1997, 323: 181-92.
120. Kulagowski, J.J., Baker, R., Curtis, N.R. et al. 3'-(Aryl-methyl)-and 3'-(aryloxy)-3-phenyl-4-hydroxyquinolin-2(1H)-ones: Orally active antagonists of the glycine site on the NMDA receptor. J Med Chem 1994, 37: 1402-5.
121. Carling, R.W., Leeson, P.D., Moore, K.W. et al. 4-Substituted-3-phenylquinolin-2(1H)-ones: Acidic and nonacidic glycine site N-methyl-D-aspartate antagonists with in vivo activity. J Med Chem 1997, 40: 754-65.
122. Priestley, T., Laughton, P., Macaulay, A.J., Hill, R.G., Kemp, J.A. Electrophysiological characterization of the antagonist properties of two novel NMDA receptor glycine site antagonists, L-695,902 and L-701,324. Neuropharmacology 1996, 35: 1573-81.